

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 25, 2006

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

Dr. Adel A.F. Mahmoud was elected to the Board of Directors of Becton, Dickinson and Company ("BD"), effective July 25, 2006. Dr. Mahmoud has been appointed to the Corporate Affairs Committee and the Finance Committee of the Board. A copy of the press release issued by BD in connection with Dr. Mahmoud's election is attached hereto as Exhibit 99.1.

Dr. Mahmoud is Chief Medical Advisor, Vaccines and Infectious Diseases of Merck & Co., Inc. ("Merck") in Whitehouse Station, New Jersey. Dr. Mahmoud is scheduled to retire from Merck, effective September 1, 2006. During BD's 2005 fiscal year, sales of BD to Merck were approximately \$32 million.

ITEM 8.01 OTHER EVENTS.

On July 25, 2006, BD issued a press release announcing the declaration of a quarterly dividend. A copy of the press release is attached hereto as Exhibit 99.2.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1 Press release dated July 25, 2006, which is filed pursuant to Item 5.02.

99.2 Press release dated July 25, 2006, which is filed pursuant to Item 8.01.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: July 25, 2006

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1	Press release dated July 25, 2006, which is filed pursuant to Item 5.02.
99.2	Press release dated July 25, 2006, which is filed pursuant to Item 8.01.



News Release

Contact:

Colleen T. White, Corporate Communications – 201-847-5369
Patricia A. Spinella, Investor Relations – 201-847-5453

BD BOARD OF DIRECTORS ELECTS DR. ADEL A.F. MAHMOUD

Franklin Lakes, NJ (July 25, 2006)— BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has elected Adel A.F. Mahmoud, M.D., Ph.D. to its Board of Directors. With his election, the BD board now consists of 12 members, 11 of whom are independent.

Dr. Mahmoud, 64, has been named Chief Executive of the Global HIV Vaccine Enterprise, a global alliance dedicated to accelerating the development of a preventive HIV vaccine, effective September 1, 2006. He is currently Chief Medical Advisor, Vaccines and Infectious Diseases at Merck & Co., Inc. From 1999 to 2005, Dr. Mahmoud served as President, Merck Vaccines and Member, Management Committee, where he managed Merck's extensive vaccine portfolio. Prior to joining Merck, Dr. Mahmoud served as Chairman of Medicine and Physician-in-Chief at Case Western Reserve University and University Hospitals of Cleveland.

"I am delighted to welcome Adel Mahmoud, a distinguished scientist, physician and business leader, to our board," said Edward J. Ludwig, BD's Chairman, President and Chief Executive Officer. "Dr. Mahmoud's infectious disease knowledge and significant work in the field of vaccines will be invaluable as BD continues its focus on unmet global healthcare needs, including HIV/AIDS."

Dr. Mahmoud received his M.D. degree from the University of Cairo, Faculty of Medicine, a D.P.H. degree from the University of Ain Shams, Faculty of Medicine and a Ph.D. from the University of London, School of Hygiene and Tropical Medicine and the Hospital for Tropical Diseases. He is a fellow of the American College of Physicians and a member of the Expert Advisory Panel on Parasitic Diseases of the World Health Organization and the Institute of Medicine of the National Academy of Sciences. He served on the National Advisory Allergy and Infectious Diseases Council and is a past-president of the Central Society for Clinical Research and International Society for Infectious Diseases.

ABOUT BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.



News Release

Contact:

Colleen T. White, Corporate Communications – 201-847-5369
Patricia A. Spinella, Investor Relations – 201-847-5453

BD BOARD DECLARES DIVIDEND

Franklin Lakes, NJ (July 25, 2006) – The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 21.5 cents per common share. The dividend will be payable on September 29, 2006 to holders of record on September 8, 2006. The indicated annual dividend rate is 86 cents per share.

ABOUT BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
